GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PCRX
Pacira BioSciences is a pharmaceutical company specializing in non-opioid pain medications. Its stock price is dependent on sales of its flagship product, Exparel, used for post-operative pain relief, and its adoption in hospitals.
Share prices of companies in the market segment - Pharma other
Pacira BioSciences is a pharmaceutical company specializing in non-opioid pain medications, such as Exparel. We classify it in the Pharma Other sector, and the chart below reflects the dynamics of the entire pain management industry.
Broad Market Index - GURU.Markets
Pacira BioSciences is a pharmaceutical company specializing in non-opioid pain management solutions, specifically EXPAREL for postoperative care. It is a component of the GURU.Markets index. The chart below represents the market. See how Pacira shares compare to the pharmaceutical sector.
Change in the price of a company, segment, and market as a whole per day
PCRX - Daily change in the company's share price PCRX
Daily fluctuations in Pacira BioSciences, a pain reliever, reflect the state of the post-operative care market. Change_co shows the sensitivity to sales of the key product. This metric is the basis for analysis in the specialty pharmaceuticals sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma other
Pacira BioSciences, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to PCRX, which focuses on non-opioid painkillers, helps understand its unique market position.
Daily change in the price of a broad market stock, index - GURU.Markets
Pacira is a pharmaceutical company specializing in non-opioid pain medications. The pharmaceutical sector working on opioid alternatives is volatile. The chart below reflects the average fluctuations in this niche, helping to assess Pacira's risks and potential.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PCRX
Pacira is a biopharmaceutical company specializing in non-opioid pain medications. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough products.
Annual dynamics of market capitalization of the market segment - Pharma other
Pacira BioSciences, Inc. is a pharmaceutical company specializing in non-opioid pain medications. Its key product, Exparel, is an alternative to opioids for postoperative care. This chart shows how its fight against the opioid crisis and efforts to expand the use of its medications are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pacira BioSciences is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PCRX
Pacira, a pharmaceutical company, depends on the success of its painkillers for its market share. The monthly fluctuations in the chart reflect sales data for its flagship product, Exparel, used for postoperative pain relief, and its adoption in clinical practice.
Monthly dynamics of market capitalization of the market segment - Pharma other
Pacira BioSciences specializes in non-opioid pain relief solutions, particularly post-operative. The company's success depends on the clinical adoption of its products as alternatives to traditional analgesics. The pharmaceutical sector chart provides a general overview of how successfully Pacira is promoting its innovative products in a conservative market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of pharmaceutical companies with successful commercial products can move independently of the market. The chart below shows general trends. Does Pacira BioSciences follow the growth of its painkiller sales, or is its stock subject to overall sentiment in the healthcare sector?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PCRX
Pacira BioSciences, a pharmaceutical company specializing in non-opioid painkillers, whose weekly stock price reflects the fight against the opioid crisis. The volume of its products used in surgery and regulatory news shape short-term trends.
Weekly dynamics of market capitalization of the market segment - Pharma other
Pacira, like other specialty pharmaceutical companies, is part of a volatile sector. This chart compares its performance with the industry to see how much of its weekly fluctuations are driven by general pharma regulatory news and how much by specific sales data for its painkillers.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Pacira BioSciences specializes in non-opioid painkillers. Demand for its products is driven by the fight against the opioid crisis. The chart will show how PCRX stock price is unaffected by overall market fluctuations, riding the wave of its technology adoption.
Market capitalization of the company, segment and market as a whole
PCRX - Market capitalization of the company PCRX
The Pacira BioSciences chart is a financial roadmap for the fight against opioid addiction. The market capitalization of this company, whose main product, Exparel, is a long-acting post-operative pain reliever, reflects the demand for opioid alternatives. Its dynamics are a barometer of how much the healthcare system is willing to pay to reduce the risk of addiction.
PCRX - Share of the company's market capitalization PCRX within the market segment - Pharma other
Pacira BioSciences is a company focused on providing non-opioid pain management solutions. Its flagship product, Exparel, is used for post-surgical pain management. Its market share reflects its leadership in this important medical niche. The chart below shows how much the market is betting on combating the opioid crisis.
Market capitalization of the market segment - Pharma other
Pacira BioSciences specializes in non-opioid painkillers. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide the backdrop against which Pacira is addressing the pressing social problem of opioid addiction.
Market capitalization of all companies included in a broad market index - GURU.Markets
Pacira BioSciences is a pharmaceutical company specializing in non-opioid painkillers for the post-operative period. Its market capitalization chart tells the story of the fight against the opioid crisis, demonstrating how alternative pain management methods are becoming increasingly valuable in modern medicine.
Book value capitalization of the company, segment and market as a whole
PCRX - Book value capitalization of the company PCRX
Pacira BioSciences' book value is its pain-relieving manufacturing capacity. The chart below shows the underlying financial strength of its business. Its growth reflects investments in expanding production to meet hospital demand for its innovative products.
PCRX - Share of the company's book capitalization PCRX within the market segment - Pharma other
Pacira BioSciences specializes in non-opioid painkillers. The production of its innovative drugs requires specialized and certified manufacturing facilities. The asset share chart shows how the company is investing in establishing its own physical manufacturing facilities for its key products.
Market segment balance sheet capitalization - Pharma other
Pacira BioSciences specializes in non-opioid painkillers. Its flagship product requires complex manufacturing. A book value chart helps assess how the company balances intangible assets (patents) with the need to invest in capital-intensive production facilities.
Book value of all companies included in the broad market index - GURU.Markets
Pacira BioSciences' book value lies in its production facilities for innovative painkillers. The company's assets include its factories producing long-acting non-narcotic analgesics, such as EXPAREL. This provides the necessary resources to offer an alternative to opioids in the postoperative period.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PCRX
Pacira BioSciences specializes in non-opioid pain medications, such as Exparel. The company's book value is modest. Its market capitalization, however, reflects Exparel's dominant position in the postoperative pain relief market and the enormous societal need for alternatives to opioids.
Market to book capitalization ratio in a market segment - Pharma other
Pacira BioSciences specializes in non-opioid pain medications. Its value is driven by the success of its flagship product, Exparel. The chart shows how market expectations for this drug and future developments compare to its tangible assets. This represents an estimate of its share of the pain management market.
Market to book capitalization ratio for the market as a whole
Pacira BioSciences specializes in non-opioid pain relief solutions. The company's main asset is its flagship drug, EXPAREL. Its market valuation is almost entirely dependent on its sales and potential for expansion. The chart shows how the market values a company focused on a single, successful product that addresses a pressing social problem.
Debts of the company, segment and market as a whole
PCRX - Company debts PCRX
Pacira BioSciences, a specialist in non-opioid painkillers, uses debt to commercialize its products and expand their use. This chart shows how the company finances the marketing of its flagship drug and clinical trials to secure approval for new indications. Debt accelerates market penetration.
Market segment debts - Pharma other
Pacira BioSciences specializes in non-opioid pain management solutions. For a pharmaceutical company with a flagship product, debt can be a tool for funding marketing efforts, expanding indications, and R&D. The chart shows how Pacira manages its capital to maximize the potential of its flagship drug.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PCRX
Pacira BioSciences specializes in non-opioid pain management solutions. The company's success depends on its key product, EXPAREL. This chart shows how the company funds its research and marketing. It helps assess whether the company is diversifying risks or using debt to maximize market penetration of its flagship drug.
Market segment debt to market segment book capitalization - Pharma other
Pacira BioSciences specializes in non-opioid pain medications, such as Exparel, used post-surgically. This is an important niche in the fight against the opioid crisis. The chart shows the overall debt burden in the pharmaceutical industry, helping to understand how the company finances marketing and research to expand the use of its products.
Debt to book value of all companies in the market
Pacira BioSciences, specializing in non-opioid pain relief, operates in an important medical niche. This chart shows the overall debt burden of the economy. It helps assess how immune the company's business is to economic downturns. Demand for effective post-operative pain relief is unlikely to be affected by the overall economic situation.
P/E of the company, segment and market as a whole
P/E - PCRX
Pacira BioSciences specializes in non-opioid pain management solutions, specifically Exparel. This chart reflects the company's fight against the opioid crisis. A high value indicates investor confidence that hospitals and surgeons will increasingly use alternative anesthesia methods, which will drive sales growth for the company's core product.
P/E of the market segment - Pharma other
Pacira BioSciences is in the specialty pharmaceuticals sector. This chart shows the average P/E for this industry. If the company's P/E is higher than the industry average, it indicates that investors view its non-opioid analgesic, Exparel, as a product with significant growth potential, putting it ahead of other pharmaceutical companies.
P/E of the market as a whole
Pacira BioSciences specializes in non-opioid pain management solutions, such as Exparel for post-operative pain management. The company is benefiting from the fight against the opioid epidemic. This chart shows sentiment in the pharmaceutical sector. It helps understand how the market views the potential of Exparel and other Pacira products to change pain management standards and reduce opioid addiction.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PCRX
Pacira BioSciences is a pharmaceutical company specializing in non-opioid pain relief solutions. This chart reflects market growth expectations for its flagship product, EXPAREL, for postoperative pain relief. Future revenue depends on expanding the drug's use in surgery and addressing the opioid crisis.
%20P%2FE%20PCRX&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PCRX&v=1772487994501 "Chart of the company's future (projected) P/E PCRX")
Future (projected) P/E of the market segment - Pharma other
Pacira BioSciences specializes in non-opioid pain management solutions, such as Exparel for post-operative pain management. This chart compares the company's future profitability expectations with those of the pharmaceutical sector. It demonstrates the extent to which investors believe in the potential of its products as an alternative to opioids and the success of its clinical developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772487994507 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Pacira BioSciences specializes in non-opioid pain medications, such as EXPAREL, for post-operative pain management. Demand for their products is driven by the number of surgical procedures and the medical community's commitment to reducing opioid use. The overall economic climate, illustrated in this graph, influences the volume of elective surgeries in hospitals.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772487994509 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PCRX
Pacira BioSciences is a pharmaceutical company specializing in non-opioid painkillers, such as Exparel. Its financial performance depends on the volume of its medications used in hospitals and surgical centers. This chart shows how efforts to promote opioid alternatives and expand indications impact sales and profitability.
Profit of companies in the market segment - Pharma other
Pacira BioSciences specializes in non-opioid pain management solutions. Its flagship product, Exparel, is used to manage post-operative pain. This chart, showing overall profitability in the pharmaceutical sector, reflects the fight against the opioid crisis. Pacira's success in promoting alternatives to opioids directly impacts treatment standards and the financial performance of the entire industry.
Overall market profit
Pacira BioSciences specializes in non-opioid pain management solutions. Its flagship product, Exparel, is used to manage post-surgical pain, helping combat the opioid crisis. The company's success is driven by medical demand and changing clinical practices, rather than by general economic trends, highlighting the importance of innovation in medicine.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PCRX
Pacira BioSciences specializes in non-opioid pain management solutions. The future profit projections you see are primarily driven by sales of its flagship drug, Exparel. Analysts estimate the drug's increased use in surgery as an alternative to opioids in the context of the fight against the opioid crisis in the US.
%20profit%20of%20the%20company%20PCRX&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PCRX&v=1772487994521 "Graph of future (projected) profit of the company PCRX")
Future (predicted) profit of companies in the market segment - Pharma other
Pacira BioSciences specializes in developing non-opioid pain medications for the post-operative period. This chart shows revenue forecasts for the entire pharmaceutical sector. It allows one to assess how the company's products, which address the pressing social problem of opioid addiction, compare to overall healthcare trends and needs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772487994524 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Pacira BioSciences specializes in non-opioid pain management solutions. Demand for its products is driven by the medical industry's commitment to combating opioid addiction. This factor is a stronger driver than overall economic conditions. However, this chart is important because hospitals' financial health affects their willingness to introduce new, albeit more effective, medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772487994529 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PCRX
Pacira BioSciences specializes in developing non-opioid painkillers, such as EXPAREL for post-operative pain management. This metric, which correlates market capitalization with sales, reflects the importance of combating the opioid crisis. It reflects the premium investors pay for its products, which offer a safe alternative to traditional analgesics.
P/S market segment - Pharma other
Pacira BioSciences specializes in developing non-opioid pain management solutions. Its flagship product, Exparel, is used to manage post-surgical pain, reducing the need for opioids. This chart shows the market premium the pharmaceutical sector is willing to pay for revenue, demonstrating how much investors value Pacira's efforts to combat the opioid crisis.
P/S of the market as a whole
Pacira BioSciences is a pharmaceutical company focused on providing non-opioid pain management solutions. Its flagship product, EXPAREL, is used to manage post-surgical pain. This chart helps understand how investors value companies solving important medical problems, like the opioid crisis, relative to the overall market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PCRX
Pacira BioSciences specializes in developing non-opioid pain medications. This chart shows how the market values the company based on its projected future sales, primarily for Exparel. It reflects expectations for the fight against the opioid crisis and the demand for alternative pain relief methods in surgery.
%20P%2FS%20PCRX&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PCRX&v=1772487994541 "The graph of the company's future (projected) P/S PCRX")
Future (projected) P/S of the market segment - Pharma other
Pacira BioSciences is a pharmaceutical company specializing in non-opioid pain management solutions. Its flagship product, Exparel, is used to manage post-surgical pain. This chart compares investor expectations for its future revenue with the sector. The high valuation reflects hopes for addressing the opioid crisis and the growing use of its products in surgery.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772487994544 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Pacira BioSciences develops non-opioid pain medications that aid post-surgical recovery. The company's growth is driven by the fight against the opioid epidemic and the demand for safer analgesics. This graph of investor expectations reflects their belief that medical innovations can address pressing social issues and be commercially successful.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772487994552 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PCRX
This chart reflects the fight against the opioid crisis through sales of Pacira BioSciences. The company's primary revenue comes from EXPAREL, a non-opioid analgesic for postoperative pain relief. Revenue growth demonstrates how successfully hospitals and surgeons are transitioning to safer alternatives for pain management, reducing the risk of addiction.
Sales of companies in the market segment - Pharma other
Pacira BioSciences specializes in the development of non-opioid pain medications. The company's flagship product provides long-lasting pain relief after surgery, reducing the need for opioids. This chart represents the total revenue of the entire pharmaceutical pain management market, where Pacira offers innovative and safe solutions.
Overall market sales
Pacira BioSciences, Inc. specializes in non-opioid pain relief solutions, particularly post-operative. Demand for its flagship product, Exparel, depends on the number of surgical procedures. This trend, reflecting the overall economic situation, influences the number of elective surgeries. During periods of economic growth, people undergo more elective procedures, increasing demand for Pacira products.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PCRX
Pacira BioSciences is a pharmaceutical company specializing in non-opioid pain management solutions. Its flagship product, Exparel, is used to manage post-operative pain. This chart reflects analysts' forecasts for growing demand for opioid alternatives in surgery and the expansion of the company's product portfolio.
%20sales%20of%20the%20company%20PCRX&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PCRX&v=1772487994573 "Schedule of future (projected) sales of the company PCRX")
Future (projected) sales of companies in the market segment - Pharma other
Pacira BioSciences specializes in non-opioid pain management solutions. This chart details projected sales of their flagship product, Exparel, and other medications. It provides insight into analysts' perspectives on the opioid crisis and the demand for alternative post-surgical pain management methods.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772487994578 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Healthcare spending forecasts, particularly in the area of postoperative pain relief, which are part of the overall expectations in this chart, are important for Pacira BioSciences. The company offers non-opioid analgesics. Demand for its products is growing as the healthcare system seeks ways to combat the opioid crisis.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772487994581 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PCRX
Pacira BioSciences specializes in non-opioid pain management solutions. This chart demonstrates profitability centered around its flagship product, EXPAREL. The company's profitability is directly dependent on the volume of this drug used in surgery, its pricing, and the successful expansion of its indications.
Market segment marginality - Pharma other
Pacira BioSciences is a company specializing in the development of non-opioid pain medications. Its flagship product is used to manage post-surgical pain. Profitability depends on the widespread use of its products. This chart shows the average profitability in the pharmaceutical industry. It helps assess how successfully Pacira is addressing the problem of opioid addiction.
Market marginality as a whole
Pacira BioSciences is a pharmaceutical company specializing in non-opioid pain management solutions. Its flagship product is used to control post-operative pain. Demand depends on the number of surgeries. This trend, reflecting the overall economic situation, may influence the number of elective surgeries that people may postpone during periods of uncertainty.
Employees in the company, segment and market as a whole
Number of employees in the company PCRX
Pacira BioSciences specializes in non-opioid pain management solutions. This chart reflects the size of the team dedicated to research, production, and commercialization of their core product. The growth in the chart reflects the company's efforts to expand the use of their anesthetics in surgery and combat the opioid crisis, which requires an increased sales force.
Share of the company's employees PCRX within the market segment - Pharma other
Pacira BioSciences specializes in non-opioid pain management solutions, such as Exparel for postoperative pain management. This chart shows the company's share of the total number of specialists working in the field of pain management. This reflects its focus on solving the problem of opioid addiction and its innovative approach to anesthesiology.
Number of employees in the market segment - Pharma other
Pacira BioSciences is a pharmaceutical company focused on providing non-opioid pain relief solutions. This chart reflects employment in the pharmaceutical sector. The growing number of specialists working on alternative analgesics demonstrates the high social importance of combating the opioid crisis and the demand for safer pain management methods.
Number of employees in the market as a whole
Pacira BioSciences specializes in non-opioid pain management solutions. Their flagship product is used to control post-surgical pain. The company's growth depends on the adoption of their product in hospitals. This overall employment figure is not directly related. The key driver is the healthcare system's desire to reduce opioid use.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PCRX (PCRX)
Pacira BioSciences is a pharmaceutical company specializing in non-opioid painkillers. Its value is based on its flagship product and its market penetration. This chart shows how the market values their commercialized asset. Value is generated by both its intellectual property and its sales and manufacturing teams.
%20of%20the%20company%20PCRX%20(PCRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PCRX-PCRX&v=1772487994627 "Chart of market capitalization per employee (in thousands of dollars) of the company PCRX (PCRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Pacira BioSciences (PCRX) specializes in non-opioid pain relief solutions, with Exparel, their flagship product, used post-operatively. They are a pharmaceutical company with a niche focus. This chart helps assess how the market views their core product and R&D.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772487994632 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Pacira BioSciences specializes in non-opioid pain medications, such as the post-operative analgesic Exparel. The company's market capitalization is based on the success of its key products. This chart illustrates how, in the pharmaceutical industry, a team behind a single successful drug can generate enormous market value by solving an important medical problem.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772487994636 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PCRX (PCRX)
Pacira BioSciences specializes in non-opioid pain relief solutions, with their flagship product, Exparel, used post-operatively. This chart demonstrates the profitability of their sales strategy, showing how effectively their sales representatives and medical team promote this innovative product to surgeons and hospitals.
%20Chart%20PCRX%20(PCRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PCRX-PCRX&v=1772487994641 "Company Profit Per Employee (in thousands of dollars) Chart PCRX (PCRX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Pacira BioSciences is a "specialty" pharma. Their "blockbuster" is "Exparel," a "non-opioid" "long-acting" "anesthetic" for "surgery." This chart shows the benchmark for "specialty pharma." In this "B2B R&D" sector, the benchmark is *very* high. Profit per employee is "generated" by a "patent" for a "niche," "high-margin" "drug" for "hospitals."
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772487994645 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Pacira BioSciences specializes in non-opioid pain relief solutions. Their flagship product (Exparel) is a long-acting injection used post-surgery. It's a pharmaceutical that addresses a pressing social problem. This chart helps understand how a business focused on a niche hospital drug compares in terms of staff efficiency compared to the market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772487994650 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PCRX (PCRX)
Pacira BioSciences specializes in non-opioid pain management solutions. Its revenue per employee is directly tied to the success of its flagship product, EXPAREL. The chart shows how effectively the company's commercial team is promoting this drug in hospitals and among surgeons, striving to make it the standard for postoperative pain management.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PCRX-PCRX&v=1772487994654 "Sales chart per company employee PCRX (PCRX)")
Sales per employee in the market segment - Pharma other
Pacira BioSciences specializes in non-opioid pain relief solutions. Their flagship product is Exparel, a long-acting anesthetic administered during surgery. This chart demonstrates the success of their commercial team. It reflects their ability to convince hospitals and surgeons to use their premium product to improve patient recovery.
Sales per employee for the market as a whole
Pacira BioSciences (PCRX) is a pharmaceutical company specializing in non-opioid pain management solutions. Their flagship product is Exparel, a long-acting injectable anesthetic used post-surgically. This chart shows the effectiveness of commercializing this niche drug. Pacira's success depends on the adoption of Exparel in hospitals. The growth of this metric reflects successful sales and the product's high margins.
Short shares by company, segment and market as a whole
Shares shorted by company PCRX (PCRX)
Pacira BioSciences specializes in non-opioid pain management solutions. Their flagship product is Exparel, a long-acting injectable anesthetic used after surgery. This chart shows bearish bets. Skeptics may question Exparel's growth rate, point to competition, or point to the risks associated with the company's reliance on virtually one product.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PCRX-PCRX&v=1772487994669 "Short Shares Chart for the Company PCRX (PCRX)")
Shares shorted by market segment - Pharma other
Pacira BioSciences (PCRX) produces non-opioid painkillers (Exparel) used to relieve post-surgical pain. This chart shows bets against the pharmaceutical sector. The shorts here may be related to concerns that insurance companies will restrict the use of the expensive Exparel or that competition in the post-surgical pain relief market will intensify.
Shares shorted by the overall market
Pacira BioSciences specializes in non-opioid painkillers, often used in elective surgeries. This seemingly stable medical business has its vulnerabilities. When this chart shows rising fears, it reflects recession fears. During such periods, consumers tend to postpone elective medical procedures, which reduces demand for Pacira products.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PCRX (PCRX)
Pacira BioSciences produces non-opioid painkillers (Exparel). Its business depends on the volume of elective surgeries. This chart above 70 may reflect strong demand for surgeries. Oversold levels (<30) are often associated with concerns about patients postponing elective procedures due to the recession.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PCRX-PCRX&v=1772487994682 "RSI 14 indicator chart for the company's stock PCRX (PCRX)")
RSI 14 Market Segment - Pharma other
Pacira BioSciences specializes in non-opioid pain relief solutions. Its flagship product, Exparel, is a long-acting injectable anesthetic used post-surgically. This chart shows the overall sentiment in the specialty pharmaceutical sector. It helps us understand whether PCRX's performance is driven by market share competition or a general "wave" across the industry.
RSI 14 for the overall market
Pacira BioSciences (PCRX) produces non-opioid painkillers. This schedule is less important to the company than regulatory decisions. Demand for its products (opioid alternatives) is stable. In times of panic, investors may value defensive demand in healthcare, although they are wary of generic competition.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PCRX (PCRX)
Pacira BioSciences (PCRX) is a pharmaceutical company focused on non-opioid pain management solutions. Its flagship product, Exparel, is a long-acting local anesthetic used post-operatively. This chart shows the average analyst forecast, reflecting their assessment of Exparel's sales volume and its adoption in surgical practice.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PCRX-PCRX&v=1772487994697 "A chart showing analyst consensus forecasts for the expected stock price. PCRX (PCRX)")
The difference between the consensus estimate and the actual stock price PCRX (PCRX)
Pacira (PCRX) is a leader in non-opioid pain management. Its flagship product, Exparel, is a long-acting local anesthetic used post-operatively instead of opioids. This chart shows the difference between the consensus estimate and the price. It reflects analyst confidence in Exparel's future growth and the company's R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PCRX-PCRX&v=1772487994701 "A chart showing the difference between the consensus forecast and the actual stock price. PCRX (PCRX)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Pacira BioSciences is a pharmaceutical company whose flagship product, Exparel, is a long-acting non-opioid analgesic used to reduce post-operative pain. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe in the trend toward opioid-free surgery.
Analysts' consensus forecast for the overall market share price
Pacira BioSciences (PCRX) is the maker of a non-opioid pain reliever (Exparel) for post-operative care. This chart of overall market sentiment is important. Optimism = high employment (people have insurance) and are willing to undergo elective surgeries (where Exparel is needed). Pessimism (recession) = postponement of elective surgeries.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PCRX
Pacira BioSciences is a pharmaceutical company focused on non-opioid pain relief. Their flagship product is Exparel, a long-acting injection used to control post-surgical pain. This chart evaluates their efforts to combat the opioid crisis, measuring the rate of adoption of Exparel in hospitals as an alternative to traditional narcotic analgesics.
AKIMA Market Segment Index - Pharma other
Pacira (PCRX) is a leader in non-opioid pain relief; the company produces Exparel, a long-acting injection used in surgery to control pain after surgery. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this niche (non-opioid) model (PCRX) differentiate itself from the average pharmaceutical company?
The AKIM Index for the overall market
Pacira BioSciences is a pharmaceutical company focused on non-opioid pain relief (Exparel) for surgical patients. This chart, which reflects the market average, provides a macro backdrop. It helps assess how PCRX, which is dependent on elective surgery volumes and generic competition, compares to overall economic trends.
